| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5575 |
| filingDate |
2002-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6ce72abebb970ffce43a787ecdb4991 |
| publicationDate |
2005-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2005014837-A1 |
| titleOfInvention |
Method for treating ocular hypertension and glaucoma |
| abstract |
A method for treating ocular hypertension and glaucoma, which comprises an administration of eye drops comprising a 15-keto-prostaglandin compound as an active ingredient to a subject in need of such treatment in a single administration volume of at least 20 μL/eye is disclosed. According to the present method, the intraocular pressure reducing effect of the compound is surprisingly augmented. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11253394-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10206813-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11426306-B2 |
| priorityDate |
2001-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |